Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 7;16(1):112-8.
doi: 10.3748/wjg.v16.i1.112.

Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin

Zhi-Yu Xiao  1 , Wei Wu, Navada Eagleton, Huan-Qing Chen, Jing Shao, Hong Teng, Tian-Hao Liu, Zhi-Min Jiang, He-Rui Yao
Affiliations

Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin

Zhi-Yu Xiao et al. World J Gastroenterol. .

Abstract

Aim: To investigate whether silencing Fas-associated phosphatase 1 (FAP-1) expression enhances the efficiency of chemotherapy for colon carcinoma with oxaliplatin.

Methods: Expression of FAP-1 in mRNA and protein was detected by reverse transcription polymerase chain reaction (RT-PCR) and flow cytometry. Small interfering RNA (siRNA) was designed according to the FAP-1 mRNA sequence. Cell proliferation was evaluated by methyl thiazolyl tetrazolium (MTT) assay. Anenxin V- and propidine iodine (PI) were assayed by flow cytometry for the detection of apoptosis.

Results: The expression of FAP-1 was increased in SW480 cells after chemotherapy with oxaliplatin. Transfection of FAP-1 siRNA into SW480 cells silenced the expression of FAP-1 and consequently abolished the inhibitory function of Fas/FasL-mediated apoptosis pathway, thus increasing the efficacy of chemotherapy for colon carcinoma with oxaliplatin.

Conclusion: RNA interference combined with conventional chemotherapy is more effective against colon cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of Fas-associated phosphatase 1 (FAP-1) mRNA (A) and protein (B) after oxaliplation administration. Oxaliplatin promotes FAP-1 expression of SW480 cells at 0, 24, 48 and 72 h after chemotherapy. bP < 0.01 vs 0 h group.
Figure 2
Figure 2
Small interfering RNA (siRNA) silencing FAP-1 expression in siRNA 1709 group (A and C) and at the concentration of 60 nmol/L (B and D). bP < 0.01 vs 0 h group.
Figure 3
Figure 3
FAP-1 siRNA increasing the inhibitory effect of oxaliplatin on proliferation of SW480 cells.
Figure 4
Figure 4
FAP-1 siRNA enhancing the apoptosis inducing effect of oxaliplatin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. Carrato A. Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res. 2008;2:S42–S46. - PMC - PubMed
    1. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528–530. - PubMed
    1. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med. 1994;179:873–879. - PMC - PubMed
    1. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365. - PubMed

Publication types

MeSH terms